We are a forward-thinking, mid-size contract research organization, with locations in Canada and the U.S., offering biopharmaceutical companies of all sizes a proven, flexible approach to early drug development including preclinical safety testing, clinical pharmacology, bioanalysis and research services. Focused on your success … always available and always looking ahead. Moving in unison to deliver big impact with a personal touch.
Focused on your needs, our specialists provide appropriate support for precision bioanalysis, and a full range of research services for a wide range of study types — working with you to accelerate development, meet your milestones, and ensure compliant, on-time regulatory submissions for your drug candidates.
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Working as a flexible, attentive extension of your team, we offer all you need to move your molecule forward.